1.70
+2.41%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pyxis Oncology
From its filings with the US Securities and Exchange Commission
Pyxis Oncology is based in Boston, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PYXS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $13.9m and a net loss of $79.6m. At that date it held total assets of $91.5m and shareholders' equity of $53.4m.
Pyxis Oncology is a clinical-stage oncology company advancing a development strategy focused on addressing unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcinoma (HNSCC).
Our lead product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational novel antibody-drug conjugate (ADC) that uniquely targets the splice variant of fibronectin, extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the extracellular matrix (ECM) in the tumor microenvironment (TME). EDB+FN is an isoform of fibronectin present in tumors that is negligibly expressed in normal adult tissues and facilitates cancer progression by playing multiple roles including promoting cell proliferation, adhesion, and migration, activating the integrin signaling pathway, stimulating angiogenesis and vascular remodeling, driving epithelial-mesenchymal transition (EMT), and establishing the pre-metastatic niche. We believe EDB+FN is a compelling target for cancer therapeutics as the physiological expression of EDB+FN is very low in healthy adult tissues, yet it is found to be highly expressed in a variety of solid tumors.
Quoted from its 10-K, filed 23 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Oct 2021
- Employees
- 67,000
- Website
- pyxisoncology.com ↗
- Head office
- 321 HARRISON AVENUE, BOSTON, MA, 02118
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. John FlavinIndependent Chairman Of The Board, since 2019$230,706
- Dr. Lara SullivanDirector, President, Chief Executive Officer and Chief Medical Officer, since 2019$7.1m
- Mr. Jitendra WadhanePrincipal Financial Officer, Senior Vice President - Finance
- Mr. Thomas CivikIndependent Director$189,533
- Mr. Darren ClineIndependent Director$193,206
- Dr. Jakob DupontIndependent Director$316,859
- Dr. Rachel HumphreyIndependent Director$323,278
- Dr. Freda Lewis-HallIndependent Director$179,889
- Mr. Michael MetzgerIndependent Director$257,657
- Mr. Santhosh PalaniIndependent Director$493,634
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is headquartered in Boston, Massachusetts.
- Employs 67,000 full-time employees.
- Focuses on developing a multi-modality portfolio of therapeutics for difficult-to-treat cancers.
Weaknesses
- No specific weaknesses mentioned in the provided information.
- No financial data provided for analysis.
- No details on product pipeline success rates or clinical trial results.
Opportunities
- Potential to expand the multi-modality portfolio of therapeutics.
- Opportunity to improve quality of life for patients through targeted cancer treatments.
- Growth potential in the biotechnology sector for cancer therapeutics.
Threats
- No specific threats mentioned in the provided information.
- No market competition details provided.
- No regulatory challenges or risks described.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.